Pediatric immunization with inactivated EV71 vaccine reduced the average incidence rate of EV71 HFMD by 60% (95% PI, 41-72%) compared to predicted rates without immunization.
Observational (n=279,352)
No
Does pediatric immunization with inactivated EV71 vaccine reduce the incidence of EV71 HFMD in children?
Programmatic vaccination against EV71 is effective in reducing the incidence of childhood HFMD in a real-world setting.
Effect estimate: 60% reduction (95% CI 41-72)
BACKGROUND: Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), associated with severe manifestations of the disease. Pediatric immunization with inactivated EV71 vaccine was initiated in 2016 in the Asia-Pacific region, including China. We analyzed a time series of HFMD cases attributable to EV71, coxsackievirus A16 (CA16), and other enteroviruses in Chengdu, a major transmission center in China, to assess early impacts of immunization. METHODS: Reported HFMD cases were obtained from China's notifiable disease surveillance system. We compared observed postvaccination incidence rates during 2017-2018 with counterfactual predictions made from a negative binomial regression and a random forest model fitted to prevaccine years (2011-2015). We fit a change point model to the full time series to evaluate whether the trend of EV71 HFMD changed following vaccination. RESULTS: Between 2011 and 2018, 279 352 HFMD cases were reported in the study region. The average incidence rate of EV71 HFMD in 2017-2018 was 60% (95% prediction interval PI, 41%-72%) lower than predicted in the absence of immunization, corresponding to an estimated 6911 (95% PI, 3246-11 542) EV71 cases averted over 2 years. There were 52% (95% PI, 42%-60%) fewer severe HFMD cases than predicted. However, the incidence rate of non-CA16 and non-EV71 HFMD was elevated in 2018. We identified a significant decline in the trend of EV71 HFMD 4 months into the postvaccine period. CONCLUSIONS: We provide the first real-world evidence that programmatic vaccination against EV71 is effective against childhood HFMD and present an approach to detect early vaccine impact or intended consequences from surveillance data.
Head et al. (Wed,) conducted a observational in Hand, foot, and mouth disease (HFMD) (n=279,352). Inactivated EV71 vaccine vs. Counterfactual predictions (no immunization) was evaluated on Incidence rate of EV71 HFMD (60% reduction, 95% CI 41-72). Pediatric immunization with inactivated EV71 vaccine reduced the average incidence rate of EV71 HFMD by 60% (95% PI, 41-72%) compared to predicted rates without immunization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: